Avastin (bevacizumab) is a useful adjunct for the treatment of neovascular glaucoma, but it is too soon to say if it will have a long-term impact on glaucoma therapy.
Avastin (bevacizumab) is a useful adjunct for the treatment of neovascular glaucoma, but it is too soon to say if it will have a long-term impact on glaucoma therapy, according to Dr Stefan Scholl.
Alongside Professor Albert Augustin, Dr Scholl performed a study comprised of 25 glaucoma patients with neovascularization from diabetic retinopathy and retinal vein occlusion. Mean intraocular pressure (IOP) was 40.8 mmHg (patients receiving full topical medication). The patients received 2 mg Avastin intracamerally.
Following Avastin administration, slit lamp tests revealed some dramatic results, with regression of vessels as early as 48 hours after injection. After one week, mean IOP was 36.2mmHg, and after two weeks it was 22.8 mmHg. At three weeks it dropped to 15.9 mmHg.
"Absolutely no assumption can be made on the long-term impact of Avastin because topical medication might also be required as well as Avastin re-treatment," said Dr Scholl. "But it can be considered a useful adjunct to more stable treatments, such as photocoagulation."
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.